Report cover image

NMDA receptor antagonists - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 120 Pages
SKU # DEL18679861

Description

NMDA receptor antagonists - Pipeline Insight, 2024



DelveInsight’s, “NMDA Receptor Antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in NMDA Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
NMDA Receptor Antagonists Understanding

NMDA Receptor Antagonists: Overview

The NMDA receptor is an ionotropic receptor that allows for the transfer of electrical signals between neurons in the brain and in the spinal column. N-methyl-D-aspartate receptor is a ligand of glutamate, which is the primary excitatory neurotransmitter in the human brain. The activation of NMDA receptors has been associated with hyperalgesia, neuropathic pain, and reduced functionality of opioid receptors. Molecules that block the NMDA receptor are called NMDA-receptor antagonists. N-methyl-D-aspartate receptors are also expressed across a wide spectrum of non-neuronal cells, including central and peripheral glial cells, endothelium, bone, kidney, pancreas, and others. NMDA-receptor antagonists can be used in the management of chronic pain and Alzheimer's disease. Commercially available NMDA-receptor antagonists include ketamine, dextromethorphan, memantine, and amantadine. The opioids methadone, dextropropoxyphene, and ketobemidone are also antagonists at the NMDA receptor.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence NMDA Receptor Antagonists R&D. The therapies under development are focused on novel approaches for NMDA Receptor Antagonists.
NMDA Receptor Antagonists Emerging Drugs Chapters

This segment of the NMDA Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

NMDA Receptor Antagonists Emerging Drugs
  • NP-120 (Ifenprodil): Algernon Pharmaceuticals
NP-120 (Ifenprodil) is an N-methyl-d-aspartate (NDMA) receptor glutamate receptor antagonist specifically targeting the NMDA-type subunit 2B (Glu2NB). Ifenprodil also exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. NP-120 (Ifenprodil – brand name Cerocal) was initially developed by Sanofi in the 1990s in the French and Japanese markets for the treatment of circulatory disorders. This repurposed drug is under clinical evaluation for the treatment of idiopathic pulmonary fibrosis (IPF) and COVID 2019 infections.
  • REL 1017: Relmada Therapeutics
REL-1017 is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. The drug is currently in late-stage studies as an adjunctive treatment for MDD in adults. In April 2017, the FDA granted Fast Track designation for REL-1017 for the adjunctive treatment of major depressive disorder.

Further product details are provided in the report……..

NMDA Receptor Antagonists: Therapeutic Assessment

This segment of the report provides insights about the different NMDA Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players working on NMDA Receptor Antagonists
There are approx. 25+ key companies which are developing the NMDA Receptor Antagonists. The companies which have their NMDA Receptor Antagonists drug candidates in the most advanced stage, i.e. Phase III include, Relmada Therapeutics.
  • Phases
DelveInsight’s report covers around 25+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
NMDA Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

NMDA Receptor Antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses NMDA Receptor Antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NMDA Receptor Antagonists drugs.

NMDA Receptor Antagonists Report Insights
  • NMDA Receptor Antagonists Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
NMDA Receptor Antagonists Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing NMDA Receptor Antagonists drugs?
  • How many NMDA Receptor Antagonists drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for NMDA Receptor Antagonists?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the NMDA Receptor Antagonists therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for NMDA Receptor Antagonists and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Algernon Pharmaceuticals
  • Relmada Therapeutics
  • UCB
  • Avanir Pharmaceuticals
  • Axsome Therapeutics
  • Seelos Therapeutics
  • PharmaTher
  • Cessatech
  • ATAI Life Sciences
  • Small Pharma
  • Bexson Biomedical
  • DemeRx
Key Products
  • NP-120 (Ifenprodil)
  • REL 1017
  • Lacosamide
  • Deudextromethorphan
  • AXS-05
  • SLS-002
  • Ketamine microneedle patch
  • CT-001
  • PCN-101
  • SPL-801-B
  • BB-106
  • Ibogaine

Table of Contents

120 Pages
Introduction
Executive Summary
NMDA Receptor Antagonists: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
NMDA Receptor Antagonists – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
NMDA Receptor Antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends
NMDA Receptor Antagonists Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
REL 1017: Relmada Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
NP-120 (Ifenprodil): Algernon Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
Ketamine microneedle patch: PharmaTher
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
SPL-801-B: Small Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
NMDA Receptor Antagonists Key Companies
NMDA Receptor Antagonists Key Products
NMDA Receptor Antagonists- Unmet Needs
NMDA Receptor Antagonists- Market Drivers and Barriers
NMDA Receptor Antagonists- Future Perspectives and Conclusion
NMDA Receptor Antagonists Analyst Views
NMDA Receptor Antagonists Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us